Wedbush lowered the firm’s price target on Astria Therapeutics to $18 from $25 and keeps an Outperform rating on the shares. Astria made concurrent strategic moves with the in-licensing of an OX40 portfolio including STAR-0310 from Ichnos Sciences, and a $64M secondary offering, the analyst tells investors in a research note. The firm is encouraged that ALPHA-STAR data remains on track for mid-2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ATXS:
- Astria Therapeutics price target lowered to $18 from $20 at H.C. Wainwright
- Astria Therapeutics prices $64M underwritten offering
- Astria Therapeutics to pay $15M upfront license fee
- Astria Therapeutics enters exclusive OX40 license agreement with Ichnos Sciences
- Astria publishes data supporting STAR-0215′ profile as HAE treatment
